New FDA warning for Tysabri

 

The U.S. Food and Drug Administration has issued a safety announcement that the risk of progressive multifocal leukoencephalopathy (PML) increases with the number of infusions received of Tysabri (natalizumab) (www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm).

It takes 30 seconds

TOPICS:
Recommend to a Colleague

Related Posts

Go back to home page